Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 12 I, 2000, Pages 1355-1364

  Stangier, Joachim ^a   Su, Chung An P F ^a   Schondorfer G ^b   Roth, Willy ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b KreCo GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TELMISARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; LIVER DISEASE; MALE;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER; LIVER FAILURE; MALE; MIDDLE AGED;

EID: 0033748477     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127000004001207     Document Type: Article

References (24)

1. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991
2. Blood pressure as a cardiovascular risk factor: Prevention and treatment
3. Management of hypertension: The advent of a new angiotensin II receptor antagonist
4. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists
5. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases
6. Angiotensin-II receptors: New targets for antihypertensive therapy
7. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
8. A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist
9. Chemistry of telmisartan, a highly lipophilic angiotensin II antagonists with a long duration of action
10. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients
11. Special in vitro and in vivo investigations on the pharmacokinetics of telmisartan and its glucuronide
12. 14C]telmisartan in healthy volunteers
13. Disposition and chemical stability of telmisartan 1-O-acylglucuronide
14. Clinical pharmacokinetics in patients with liver disease
15. Fasting serum bile acid level in cirrhosis: A semi-quantitative index of hepatic function
16. Determinants of drug disposition in patients with cirrhosis
17. Effect of hepatic insufficiency on pharmacokinetics and drug dosing
18. Free drug concentration monitoring in clinical practice: Rationale and current status
19. Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and alpha 1-acid glycoprotein: Implications for binding of drugs
20. Assessing the safety profile of a new antihypertensive agent
21. Once-daily telmisartan compared with enalapril in the treatment of hypertension